Tae-Hwan Kwon Selected Research

Polyuria

1/2018	Tamoxifen attenuates development of lithium-induced nephrogenic diabetes insipidus in rats.
11/2010	Pre-existing renal failure worsens the outcome after intestinal ischaemia and reperfusion in rats.
5/2008	Aldosterone-mediated apical targeting of ENaC subunits is blunted in rats with streptozotocin-induced diabetes mellitus.
5/2008	Dysregulation of renal aquaporins and epithelial sodium channel in lithium-induced nephrogenic diabetes insipidus.
6/2007	Regulation of AQP2 in Collecting Duct : An emphasis on the Effects of Angiotensin II or Aldosterone.
4/2005	Angiotensin II AT1 receptor blockade changes expression of renal sodium transporters in rats with chronic renal failure.
3/2004	Reduced expression of renal Na+ transporters in rats with PTH-induced hypercalcemia.
1/2004	Changes of rat kidney AQP2 and Na,K-ATPase mRNA expression in lithium-induced nephrogenic diabetes insipidus.
12/2003	Segment-specific ENaC downregulation in kidney of rats with lithium-induced NDI.
11/2003	Altered expression of major renal Na transporters in rats with bilateral ureteral obstruction and release of obstruction.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tae-Hwan Kwon Research Topics

Disease

17	Nephrogenic Diabetes Insipidus 01/2020 - 12/2003
12	Polyuria 01/2018 - 01/2002
8	Neoplasms (Cancer) 05/2022 - 01/2007
8	Ureteral Obstruction 01/2019 - 11/2003
6	Breast Neoplasms (Breast Cancer) 05/2022 - 01/2011
6	Acute Kidney Injury (Acute Renal Failure) 01/2021 - 12/2003
5	Acidosis 01/2014 - 03/2003
4	Ischemia 01/2021 - 08/2004
4	Fibrosis (Cirrhosis) 01/2019 - 11/2005
3	Inflammation (Inflammations) 01/2021 - 01/2013
3	Neoplasm Metastasis (Metastasis) 01/2019 - 10/2016
3	Mood Disorders (Mood Disorder) 01/2018 - 02/2010
3	Chronic Renal Insufficiency 07/2014 - 11/2010
3	Heart Failure 09/2013 - 01/2002
3	Diabetes Insipidus 06/2007 - 05/2005
3	Hypercalcemia (Milk Alkali Syndrome) 03/2004 - 01/2002
2	Kidney Diseases (Kidney Disease) 01/2021 - 11/2018
2	Sepsis (Septicemia) 11/2020 - 08/2009
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2020 - 01/2019
2	Nephrotic Syndrome (Syndrome, Nephrotic) 09/2013 - 05/2004
2	Liver Cirrhosis (Hepatic Cirrhosis) 09/2013 - 11/2005
2	Chronic Kidney Failure (Chronic Renal Failure) 09/2013 - 04/2005
2	Azotemia 11/2010 - 04/2005
2	Shock 11/2010 - 12/2003
2	Proteinuria 11/2010 - 05/2004
2	Bone Resorption 05/2010 - 02/2009
2	Brain Ischemia (Cerebral Ischemia) 11/2008 - 10/2007
2	Ascites 11/2005 - 05/2004
2	Hypertrophy 04/2005 - 01/2004
1	Endotoxemia 11/2020
1	Hemorrhage 11/2020
1	Autoimmune Diseases of the Nervous System 01/2020
1	Body Weight (Weight, Body) 01/2020
1	Hypercholesterolemia 01/2019
1	Obesity 01/2019
1	Pheochromocytoma 04/2016

Drug/Important Bio-Agent (IBA)

16	LithiumIBA 01/2020 - 12/2003
13	SodiumIBA 09/2015 - 03/2003
12	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2003
8	Aquaporin 2IBA 06/2019 - 01/2004
8	AldosteroneIBA 01/2018 - 12/2002
8	Aquaporins (Water Channels)IBA 10/2016 - 12/2002
6	Aquaporin 5IBA 05/2022 - 01/2011
4	Therapeutic UsesIBA 01/2021 - 01/2019
4	Peptides (Polypeptides)IBA 01/2020 - 01/2007
4	Vasopressins (Vasopressin)IBA 09/2015 - 01/2002
4	Messenger RNA (mRNA)IBA 10/2011 - 01/2004
3	CytokinesIBA 11/2020 - 06/2014
3	EnzymesIBA 01/2020 - 12/2007
3	Tamoxifen FDA LinkGeneric 01/2019 - 01/2018
3	Dinoprostone (PGE2)FDA Link 01/2019 - 05/2005
3	Pharmaceutical PreparationsIBA 09/2015 - 10/2008
3	CreatinineIBA 07/2014 - 12/2003
3	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 10/2011 - 06/2007
3	salicylhydroxamic acid (SHAM)IBA 11/2010 - 12/2003
3	Adenosine Triphosphatases (ATPase)IBA 02/2009 - 01/2004
3	Fluorescein (Funduscein)FDA LinkGeneric 11/2008 - 01/2007
3	Epithelial Sodium ChannelsIBA 05/2008 - 11/2005
2	Biomarkers (Surrogate Marker)IBA 05/2022 - 06/2011
2	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2018
2	Interleukin-4 Receptors (Interleukin 4 Receptor)IBA 01/2020 - 10/2008
2	ChemokinesIBA 07/2014 - 06/2014
2	AcidsIBA 01/2012 - 08/2009
2	SymportersIBA 05/2010 - 11/2005
2	Angiotensin IIIBA 12/2009 - 04/2005
2	Hormones (Hormone)IBA 05/2008 - 02/2006
2	Transforming Growth Factor beta (TGF-beta)IBA 05/2007 - 09/2003
2	Erythropoietin FDA Link 05/2007 - 08/2004
2	alpha-MSHIBA 02/2006 - 08/2004
2	Vitamin D FDA LinkGeneric 12/2002 - 01/2002
1	PolymersIBA 01/2021
1	allithiamineIBA 11/2020
1	Thiamine (Aneurin)FDA Link 11/2020
1	Myelin-Oligodendrocyte GlycoproteinIBA 01/2020
1	TransferasesIBA 01/2020
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2020
1	Myelin Basic ProteinIBA 01/2020
1	Carnitine (L-Carnitine)FDA LinkGeneric 01/2020
1	etomoxirIBA 01/2020
1	Selective Estrogen Receptor Modulators (SERM)IBA 01/2019
1	Allopurinol (Remid)FDA LinkGeneric 01/2019
1	oxidized low density lipoproteinIBA 01/2019
1	Febuxostat FDA Link 01/2019
1	butaprostIBA 01/2019
1	Xanthine OxidaseIBA 01/2019
1	CholesterolIBA 01/2019
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019
1	CollagenIBA 01/2019
1	hydroxide ionIBA 01/2019
1	Insulin (Novolin)FDA Link 01/2019
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 11/2018
1	Bile Acids and Salts (Bile Acids)IBA 11/2018
1	SuspensionsIBA 11/2018
1	Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA 01/2018
1	GTP Phosphohydrolases (GTPases)IBA 11/2017
1	Lysine (L-Lysine)FDA Link 04/2016
1	perfosfamideIBA 09/2015

Therapy/Procedure

2	Intravenous Administration 01/2021 - 11/2008
2	Therapeutics 10/2016 - 01/2007
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2021